BWA
REGN icon

BlueSky Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

BlueSky Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-320
Closed -$247K – 123
2026
Q1 		$247K Buy
+320
New +$245K 0.03% 102

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BlueSky Wealth Advisors's REGN Position: Q2 2026 in Review

BlueSky Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 320 shares — an estimated $247K sold.

BlueSky Wealth Advisors first reported a position in REGN in Q1 2026 and held it in 1 quarter. The position peaked at $247K in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • BlueSky Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • BlueSky Wealth Advisors sold 320 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $247K.
  • BlueSky Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • BlueSky Wealth Advisors's Regeneron Pharmaceuticals position peaked at $247K in Q1 2026.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on BlueSky Wealth Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.